2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 1000

Obesity and Foot Problems in the Framingham Foot Study: Does Foot Structure or Foot Function Protect Against Hallux Valgus?
Abstract Number: 1699

Obesity and Pediatric Psoriatic Arthritis
Abstract Number: 1598

Obesity and the Risk for Development of Rheumatoid Arthritis – Results from a Population-Based Nested Case-Control Study
Abstract Number: 1703

Obesity Is Related with Active State in Psoriatic Arthritis and Rheumatoid Arthritis but Not Ankylosing Spondylitis at Real Life Biological Cohort
Abstract Number: 1112

Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 1697

Obstructive Sleep Apnea and Fatigue in Inflammatory Arthritis Patients Taking TNF-Inhibitors
Abstract Number: 839

Occupational Exposures in Patients with Systemic Sclerosis Associated with Increased Frequency of Interstitial Lung Disease and Primary Pulmonary Hypertension
Abstract Number: 2246

Occupations Involving Manual Labor Increase the Risk for Incident Knee Osteoarthritis
Abstract Number: 1567

Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Abstract Number: 1532

Occurrence of Valvular Heart Disease in Rheumatoid Arthritis: A Population Based Study
Abstract Number: 3063

Ocular Findings and Ocular Blood Flow Changes in Takayasu Arteritis: A Subclinical Reduction in Blood Flow with a Milder Clinical Course of Retinopathy
Abstract Number: 500

Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Abstract Number: 326

Older Adults without Extreme Obesity Are at Highest Risk for Accelerated Knee Osteoarthritis
Abstract Number: 2021

Omega-3 Fatty Acids Are Associated with a Lower Prevalence of Autoantibody Positivity in HLA-DR Shared Epitope Positive Subjects Who Are at Increased Risk for Future RA
Abstract Number: 554

On Drug and Drug-Free Remission By Baseline Disease Duration: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis
Abstract Number: 477

On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Abstract Number: 1914

Oncostatin M As a Potential Molecular Target in Systemic Sclerosis
Abstract Number: 139

One-Year Cost of Etanercept, Adalimumab, and Infliximab per Treated Patient with Chronic Inflammatory Arthritides in US Veterans
Abstract Number: 144

One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Abstract Number: 1672

One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1295

Online Consultation for Rheumatic Disease Patients Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Abstract Number: 1230

Only One-Third of Patients with Spondyloarthritis Are Managed By Rheumatologists
Abstract Number: 1792

Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
Abstract Number: 581

Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients
Abstract Number: 1220

Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Abstract Number: 51

Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study
Abstract Number: 1438

Oral Potassium (K+) Reduces Pain in RA: A Randomized Active Control Study of Diet Based K+ Intervention
Abstract Number: 3194

Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Abstract Number: 723

Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation
Abstract Number: 783

Osteonecrosis in Systemic Lupus Erythematosus: Predictive Factors
Abstract Number: 1702

Osteoporosis in Psoriatic Arthritis
Abstract Number: 380

Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Abstract Number: 378

Osteoporotic Fragility Tibia/Fibula Fractures Are Not Asociated with a Low Body Mass Index: An Observational Study
Abstract Number: 1825

Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
Abstract Number: 2930

Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Abstract Number: 3070

Outcome of Pregnancies in Patients with Takayasu Arteritis with Special Focus on Risk Factors and Disease Activity
Abstract Number: 585

Outcomes after Discontinuing Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis: 2 Years of ‘post-Golimumab’ after Completion of the 5-Year Extension Study in Korea
Abstract Number: 1440

Outcomes and Cost-Effectiveness of Shoulder Injections with Sonographic Needle Guidance
Abstract Number: 555

Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Abstract Number: 2941

Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance
Abstract Number: 2510

Outpatient Consultation Requests: A Failure to Communicate
Abstract Number: 3012

Over-Expression of Ubiquitin-Specific Peptidases in Systemic Sclerosis Fibroblasts Increases Responses to TGF-Beta
Abstract Number: 2178

Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Abstract Number: 1780

Oxidative Stress Protects Against Nephritis Induced By Chronic Graft Versus Host Disease

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].